Fundraising Fox
Endostim
St. Louis, US · Founded 2009 · Delaware corporation · 4 employees on LinkedIn · 2 known investors
Find your way into Endostim
Sign up to see every warm intro you have to Endostim
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Endostim team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
EndoStim develops a neurostimulation medical device system for treating drug-resistant gastroesophageal reflux disease (GERD) by restoring esophageal function while preserving normal anatomy.
Founders & leadership
EG
Eric GoornoChief Executive Officer
GW
Greg WilsonChief Financial Officer
SA
Stephen Attwood, MDSurgical Director
VS
Virender Sharma, MDChief Medical Officer
HA
Hazim AnsariChief Legal Counsel
BJ
Bevil J. HoggExecutive
PS
Peggy S. StohrExecutive
VK
Virender K. SharmaNamed on SEC filing
SP
Shai PolickerNamed on SEC filing
Board
DD
Douglas D. FrenchBoard director
JM
Jeffrey M. McDonnellBoard director
Investors · 2
Relevance Ventureslisted by Relevance VenturesNashville · $250K – $2.5M
How we know: Relevance Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Sante VenturesreportedAustin · $2M – $6M
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$34.9M disclosed across 5 rounds · 2014–2018
▶$2.8MraisedDec 2018 · 4 investors · Other Health CareRule 506(b)
▶$2.8MraisedDec 2018 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Brian FarleyDirector
- Paul V. GoodeExecutive Officer
- Alexander SchmitzDirector
- Virender K. SharmaExecutive Officer
- Douglas D. FrenchDirector
- Offering amount
- $7M
- Amount sold
- $2.8M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.1MraisedJan 2018 · 20 investors · Other Health CareRule 506(b)
▶$12.1MraisedJan 2018 · 20 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Rohan J. HoareExecutive Officer, Director
- Douglas D. FrenchDirector
- Kimberly PinsonExecutive Officer
- Alexander SchmitzDirector
- Paul GoodeExecutive Officer
- Virender K. SharmaExecutive Officer
- Offering amount
- $25M
- Amount sold
- $12.1M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.1MraisedMar 2016 · 83 investors · Other Health CareRule 506(b)
▶$11.1MraisedMar 2016 · 83 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Alexander SchmitzDirector
- Paul GoodeExecutive Officer
- Peggy S. StohrExecutive Officer
- Shai PolickerExecutive Officer
- Douglas D. FrenchDirector
- Bevil J. HoggExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $11.1M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedMay 2015 · 1 investors · Other Health CareRule 506(b)
▶$2.5MraisedMay 2015 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Bevil J. HoggExecutive Officer, Director
- Paul GoodeExecutive Officer
- Peggy S. StohrExecutive Officer
- Raul E. PerezDirector
- Douglas D. FrenchDirector
- Virender K. SharmaDirector
- Ralph G. DaceyDirector
- Jeffrey M. McDonnellDirector
- Shai PolickerExecutive Officer
- Fred C. GoadDirector
- Offering amount
- $5M
- Amount sold
- $2.5M
- Minimum investment
- $2.5M
- First sale
- May 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.4MraisedJul 2014 · 72 investors · Other Health CareRule 506(b)
▶$6.4MraisedJul 2014 · 72 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Peggy S. StohrExecutive Officer
- Raul E. PerezDirector
- Virender K. SharmaDirector
- Douglas D. FrenchDirector
- Jeffrey M. McDonnellDirector
- Ralph G. DaceyDirector
- Shai PolickerExecutive Officer
- Paul GoodeExecutive Officer
- Fred C. GoadDirector
- Bevil J. HoggExecutive Officer, Director
- Offering amount
- $7.5M
- Amount sold
- $6.4M
- Sales commissions
- $100K
- Placement agents
- Stifel, Nicolaus & Company, Incorporated, Healthios Capital Markets, LLC
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
OsmosisOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.
Companies working in the same space as Endostim.
Frequently asked questions
- What does Endostim do?
- EndoStim develops a neurostimulation medical device system for treating drug-resistant gastroesophageal reflux disease (GERD) by restoring esophageal function while preserving normal anatomy.
- Who are Endostim's investors?
- Endostim's investors include Relevance Ventures, Sante Ventures.
- How much funding has Endostim raised?
- Endostim has disclosed $34.9M raised across 5 rounds.
- Where is Endostim headquartered?
- Endostim is headquartered in St. Louis, US.